What is the recommended Argireline dosage?

Argireline dosing varies by experience level. Beginners typically start at 2mg 2x daily, moderate users at 5mg 2x daily, and aggressive protocols use 10mg 2x daily.

How do you reconstitute Argireline?

Argireline comes as a pre-filled device — no reconstitution needed.

What is the half-life of Argireline?

The half-life of Argireline is Unknown (topical peptide — no systemic PK data available). This determines how frequently you need to dose for consistent blood levels.

Argireline

Q: What are the side effects of Argireline?

Generally very well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no significant adverse events compared to vehicle control. Mild, transient skin irritation or slight redness at the application site may occur in sensitive individuals. No systemic side effects are expected due to negligible transdermal absorption — in vitro studies show less than 0.3% of applied peptide penetrates beyond the skin surface. Allergic contact dermatitis is theoretically possible but has not been reported at meaningful rates. In the blepharospasm pilot study, minor eyelid irritation was attributed to the cream formulation vehicle rather than the active peptide. No oral toxicity or primary irritation was observed at high doses in preclinical safety testing.

Anti-AgingTopicalResearchGrade AUnknown (topical peptide — no systemic PK data available) half-life

Anti-WrinkleSNARE InhibitorTopical PeptideCosmeceuticalExpression LinesBotox Alternative12 weeks on / 2 weeks off

Benefits

Reduces expression line depth by competitively inhibiting SNARE complex assembly at neuromuscular junctions

Non-invasive topical alternative to botulinum toxin injections for dynamic wrinkles

Preserves natural facial movement and expression while softening wrinkle appearance

Clinical evidence of up to 49% anti-wrinkle efficacy in randomized controlled trials

Excellent safety profile with no systemic toxicity confirmed by CIR Expert Panel review

Compatible with other anti-aging peptides including SNAP-8, GHK-Cu, and Matrixyl in combination protocols

Well-tolerated with minimal side effects in topical cosmetic formulations

Half-Life

Unknown

Route

Topical

Frequency

2x Daily

Vial Sizes

5mg, 10mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Argireline Dosage Calculator

Calculate exact syringe units for your vial and dose

About Argireline

Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic six-amino-acid peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, designed to reduce the appearance of expression wrinkles through a mechanism analogous to botulinum toxin — but applied topically rather than injected. The hexapeptide sequence is modeled after the N-terminal domain of SNAP-25 (Synaptosomal-Associated Protein of 25 kDa), specifically residues 12-17, which participate in the assembly of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex at neuromuscular junctions. By competing with endogenous SNAP-25 for binding to VAMP (vesicle-associated membrane protein), Argireline destabilizes the ternary SNARE complex that is required for calcium-dependent exocytosis of acetylcholine. This reduces neurotransmitter release at the neuromuscular junction, attenuating the repeated muscle contractions that form dynamic facial wrinkles such as forehead furrows, crow's feet, and frown lines. Unlike botulinum toxin type A, which irreversibly cleaves SNAP-25 through proteolytic action, Argireline acts as a competitive inhibitor — it modulates rather than paralyzes muscle contraction, preserving natural facial expressions while softening expression lines. The original 2002 study by Blanes-Mira et al. demonstrated that a 10% Argireline emulsion reduced wrinkle depth by up to 30% after 30 days of treatment in healthy women volunteers. A subsequent randomized, placebo-controlled study in 60 Chinese subjects showed total anti-wrinkle efficacy of 48.9% in the Argireline group versus 0% in placebo, with statistically significant reductions in all roughness parameters (p < 0.01) after 4 weeks of twice-daily application. However, other studies have produced mixed results — a 2023 double-blind study with 19 subjects found no statistically significant wrinkle reduction compared to control, and the blepharospasm pilot trial using 0.005% topical AH-8 showed trends favoring treatment but did not reach statistical significance. The primary limitation of Argireline is skin penetration: as a hydrophilic peptide (MW 889 Da), it struggles to cross the lipophilic stratum corneum. In vitro penetration studies show only 0.22% of applied peptide is retained in the human stratum corneum, with approximately 0.01% reaching the epidermis and no detectable amounts in the dermis. Advanced delivery systems including multiple water-in-oil-in-water emulsions, liposomes, and microneedle patches are being explored to improve dermal bioavailability. Argireline is classified as a cosmeceutical ingredient and is not FDA-approved for any medical indication. The Cosmetic Ingredient Review (CIR) Expert Panel has assessed acetyl hexapeptide-8 and confirmed its safety in cosmetic formulations.

Who Should Consider Argireline

Adults over 30 with early expression lines seeking non-invasive wrinkle treatment
Individuals who prefer topical anti-aging products over botulinum toxin injections
People with dynamic wrinkles on forehead, crow's feet, or glabella
Skincare enthusiasts building multi-peptide anti-aging protocols
Those seeking to extend the interval between Botox appointments with supplemental topical care
Individuals with needle aversion who want evidence-based anti-wrinkle cosmeceuticals

How Argireline Works

Argireline functions as a competitive inhibitor of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex, which is the molecular machinery responsible for neurotransmitter release at neuromuscular junctions. The SNARE complex is a ternary assembly of three proteins: syntaxin-1 and SNAP-25 (anchored to the presynaptic plasma membrane) and VAMP/synaptobrevin-2 (anchored to the synaptic vesicle membrane). When these three proteins zipper together, they generate the mechanical force needed to fuse the vesicle with the plasma membrane and release acetylcholine into the synaptic cleft. Argireline's six-amino-acid sequence (Ac-EEMQRR-NH2) mimics residues 12-17 of the SNAP-25 N-terminal SNARE motif. By competing with endogenous SNAP-25 for its binding position within the ternary complex — specifically disrupting the binary interaction between SNAP-25 and syntaxin that initiates assembly — Argireline destabilizes SNARE complex formation. This reduces the efficiency of calcium-dependent vesicle fusion and decreases acetylcholine release without fully blocking it. The functional result is attenuated contraction of facial muscles responsible for dynamic expression lines (frontalis, orbicularis oculi, corrugator supercilii), producing a visible smoothing of forehead furrows, crow's feet, and glabellar frown lines with repeated topical application. Importantly, Argireline does not cleave or permanently modify any SNARE protein — unlike botulinum toxin type A, which proteolytically cleaves SNAP-25 — so its effect is reversible and dose-dependent, allowing natural facial expression while reducing the repetitive micro-contractions that deepen wrinkles over time.

What to Expect

Week 1

No visible changes expected. Argireline begins accumulating in the upper skin layers upon twice-daily application. Some users notice a mild smoothing or tightening sensation immediately after application due to the serum vehicle. Skin tolerance is established during this period.

Weeks 2-4

Early wrinkle softening becomes apparent, especially on fine expression lines. The original Blanes-Mira study reported up to 30% wrinkle depth reduction by day 30. Surface roughness parameters begin to decrease measurably. Fine lines around the eyes and forehead show the most noticeable initial improvement.

Weeks 4-8

Peak anti-wrinkle effects are typically reached in this window. The randomized Chinese clinical trial reported 48.9% total efficacy at 4 weeks with statistically significant roughness reduction (p < 0.01). Results vary based on concentration (10% formulations outperform lower concentrations), formulation quality, and individual skin penetration characteristics.

Weeks 8-12

Maintenance of wrinkle reduction gains with continued twice-daily use. Deeper expression lines may show further gradual improvement. Best results are achieved with consistent high-concentration (10%) application combined with complementary peptides such as SNAP-8 or Matrixyl.

After stopping

Effects are not permanent. Wrinkle depth gradually returns to baseline over 4-8 weeks after discontinuation as normal SNARE complex assembly and muscle contraction patterns resume. Restarting the protocol restores benefits. No rebound worsening has been reported.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	2mg	2x Daily
Moderate	5mg	2x Daily
Aggressive	10mg	2x Daily

Note: Topical anti-wrinkle peptide also known as Acetyl Hexapeptide-3 and Acetyl Hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, MW 889 Da). Developed by Lipotec (now part of Lubrizol) and marketed under the trade name Argireline. Typically formulated in topical serums and creams at 5-10% concentration. The dosing tiers above reflect approximate mg of active peptide per topical application. Clinical studies using 10% formulations report wrinkle depth reductions of 17-49% over 4 weeks of twice-daily application. Apply to clean, dry skin on expression-line areas (forehead, crow's feet, glabella, periorbital region) before moisturizer. CAS number: 616204-22-9.

How to Inject Argireline

Apply a thin layer of Argireline serum or cream (5-10% active peptide concentration) to clean, dry skin on target expression-line areas — typically forehead, crow's feet, glabellar frown lines, and periorbital region. Use morning and evening before moisturizer and sunscreen. Allow 2-3 minutes for absorption before layering other products. Argireline is compatible with hyaluronic acid, niacinamide, vitamin C, and other peptides (SNAP-8, Matrixyl, GHK-Cu). Avoid applying immediately after strong chemical exfoliants (AHAs/BHAs at peel-strength concentrations) as compromised skin barrier may alter absorption. For enhanced penetration, consider formulations with penetration enhancers or use after gentle microneedling (0.25-0.5mm). Do not apply to broken, actively inflamed, or sunburned skin. Results are cumulative — consistent twice-daily application for at least 4 weeks is needed before evaluating efficacy.

Cycling Protocol

On Period

12 weeks

Off Period

2 weeks

Apply twice daily for 12 weeks to allow cumulative wrinkle reduction. Clinical improvement typically begins around week 2-3 and peaks at week 4-8. A 2-week break is optional — no receptor desensitization or tachyphylaxis has been reported, so continuous long-term use is commonly practiced. Effects are reversible and diminish gradually over 4-8 weeks after discontinuation as normal SNARE complex function resumes.

Pharmacokinetics

Half-Life

0min

Bioavailability

Topical: <0.3% total skin retention; no detectable systemic absorption in human skin models

Tmax

Not applicable (topical, non-systemic)

Data Confidence

low

Source: No systemic pharmacokinetic data available. Argireline is a topical cosmeceutical peptide with negligible transdermal absorption. In vitro skin penetration studies (Kraeling et al. 2015, PMID 24754410) show only 0.22% of applied peptide is retained in the human stratum corneum, ~0.01% reaches the epidermis, and no detectable amounts reach the dermis or systemic circulation. No metabolites (deacetylated H2N-EEMQRR-NH2) were found in any skin layer, indicating the peptide remains intact but does not achieve meaningful systemic exposure.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally very well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no significant adverse events compared to vehicle control. Mild, transient skin irritation or slight redness at the application site may occur in sensitive individuals. No systemic side effects are expected due to negligible transdermal absorption — in vitro studies show less than 0.3% of applied peptide penetrates beyond the skin surface. Allergic contact dermatitis is theoretically possible but has not been reported at meaningful rates. In the blepharospasm pilot study, minor eyelid irritation was attributed to the cream formulation vehicle rather than the active peptide. No oral toxicity or primary irritation was observed at high doses in preclinical safety testing.

Contraindications

Known allergy or hypersensitivity to acetyl hexapeptide-8 or any component amino acid (glutamic acid, methionine, glutamine, arginine)
Active skin infections, open wounds, or severe dermatitis at intended application sites
Pregnancy or breastfeeding (no safety data available for these populations)
Children under 18 (insufficient safety data)
History of contact dermatitis to cosmeceutical peptide products
Concurrent use at injection sites immediately following botulinum toxin treatment (allow 24-48 hours post-injection before applying topicals to treated areas)

Drug Interactions

Botulinum toxin (Botox, Dysport, Xeomin) — both target the SNARE complex; combined use may theoretically increase muscle relaxation effects. Some practitioners use Argireline between Botox appointments to extend results, but consult a dermatologist
Other SNARE-modulating topical peptides (SNAP-8, Leuphasyl/Pentapeptide-18) — additive neuromuscular effects are expected and have been studied in combination protocols; monitor for excessive facial muscle relaxation
Topical retinoids (tretinoin, adapalene) — may increase skin sensitivity when layered simultaneously; apply at separate times of day for best tolerance
High-concentration chemical peels (glycolic acid >20%, TCA peels) — compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
Topical corticosteroids — prolonged steroid use thins the epidermis and may alter peptide retention and penetration characteristics